CompletedPHASE1, PHASE2NCT01461213

Gene Therapy for Blindness Caused by Choroideremia

Studying Choroideremia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Oxford
Principal Investigator
Robert E MacLaren, MB ChB DPhil
University of Oxford, Oxford Radcliffe Hospitals NHS Trust and Moorfields Eye Hospital
Intervention
rAAV2.REP1(drug)
Enrollment
14 enrolled
Eligibility
18 years · MALE
Timeline
2011 – 2017

Study locations (4)

Collaborators

Oxford University Hospitals NHS Trust · Moorfields Eye Hospital NHS Foundation Trust · University College, London · Manchester University NHS Foundation Trust · University of Manchester · University Hospital Southampton NHS Foundation Trust · University of Southampton

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01461213 on ClinicalTrials.gov

Other trials for Choroideremia

Additional recruiting or active studies for the same condition.

See all trials for Choroideremia →

← Back to all trials